Drug Facts and Comparisons®

2002



56th edition

Facts and Comparisons®
St. Louis
A **Wolters Kluwer** Company

Drug Facts and Comparisons,® 2002 Edition

Manuscript indexed by Coughlin Indexing Services, Inc., Annapolis, Maryland.

ISBN 1-57439-110-0

Printed in the United States of America

Published by
Facts and Comparisons®
A **Wolters Kluwer** Company
111 West Port Plaza, Suite 300
St. Louis, Missouri 63146-3098
314/216-2100
Toll free customer service 1-800-223-0554
www.factsandcomparisons.com
www.drugfacts.com

Drug Facts and Comparisons® Staff

Facts and Comparisons®
St. Louis
A **Wolters Kluwer** Company

Facts and Comparisons®
Editorial Advisory Panel

Contributing Review Panel

Jonathan Abrams, MD
Professor of Medicine
Cardiology Division
University of New Mexico
Albuquerque, New Mexico

Ezra A. Amsterdam, MD, FACC
Professor, Internal Medicine
Director
Cardiac Care Unit
University of California at Davis and Sacramento
School of Medicine and Medical Center

Danial E. Baker, PharmD
Professor of Pharmacy Practice
Director, Drug Information Center
Director, Continuing Education Program
Washington State University
Spokane, Washington

Julie K. Baltz, PharmD
Clinical Research Pharmacist
National Cancer Institute
Bethesda, Maryland

Jimmy D. Bartlett, OD, DOS
Professor of Optometry and Pharmacology
Schools of Optometry and Medicine
University of Alabama at Birmingham

Shawna L. Blasing, PharmD
Drug Information Consultant
Dayton, Ohio

Lawrence R. Borgsdorf, PharmD
Pharmacist Specialist – Ambulatory Care
Kaiser Permanente
Bakersfield, California

Daniel L. Brown, PharmD
Vice-Chair of Pharmacy Practice
Director of Experiential Learning
Palm Beach Atlantic College
School of Pharmacy
Palm Beach, Florida

R. Keith Campbell, RPh, FAPP, MBA
Associate Dean/Professor of Pharmacy
Washington State University
College of Pharmacy
Pullman, Washington

Melvin D. Cheitlin, MD
Professor of Medicine
University of California, San Francisco, Cardiology Division
Associate Chief, Cardiology Division
San Francisco General Hospital
San Francisco, California

Stephen L. Dahl, PharmD
University of Missouri – Kansas City
School of Medicine
Kansas City, Missouri

Richard J. Duma, MD, PhD
Infectious Disease Division
Halifax Medical Center
Daytona Beach, Florida

Kathryn M. Edwards, MD
Department of Pediatrics
Vanderbilt University Medical School
Nashville, Tennessee

LTC Michael S. Edwards, PharmD, MS
Landstuhl Army Medical Center
APO AE 09180

Mary J. Ferrill, PharmD
Associate Dean and Professor
Palm Beach Atlantic College
School of Pharmacy
West Palm Beach, Florida

N. Rex Ghormley, OD, FAAO
Contact Lens and Vision Care Consultants, President
St. Louis, Missouri

Thomas A. Golper, MD
Professor of Medicine
Medical Director & Director of Clinical Research
Division of Nephrology
University of Arkansas for Medical Sciences
Little Rock, Arkansas

LTC. John D. Grabenstein, RPh, PhD, FAPhA, FASHP, FRSH
Medical Service Corp.
Deputy Director for Clinical Operations
Anthrax Vaccine Immunization Program
U.S. Army Medical Command

Ellen L. Hamburg, PharmD, BCPS
Associate Professor of Clinical Pharmacy
Arnold and Marie Schwartz College of Pharmacy and Health Sciences of Long Island University
State University of New York
Health Sciences Center at Brooklyn
Brooklyn, New York

Edward A. Hartshorn, PhD
Clinical Professor
University of Texas at Austin, College of Pharmacy
University of Texas
Medical Branch at Galveston
Galveston, Texas

Tina C. Hussey, PharmD
Drug Information Clinical Specialist
University of North Carolina Health Care System

Siret D. Jaanus, PhD
Southern California College of Optometry
Fullerton, California

Robert E. Kates, PharmD, PhD
President
Analytical Solutions, Inc.
Sunnyvale, California

Julio R. Lopez, PharmD
Assistant Professor, School of Pharmacy, University of the Pacific
Assistant Clinical Professor, School of Pharmacy, University of California, San Francisco
Director, Drug Information Center, VA Medical Center
Martinez, California

Susan O'Donoghue, MD
Associate Director, Cardiac Arrhythmia Center
Washington Hospital Center
Washington, DC

Richard M. Oksas, PharmD, MPh
Pharmaceutical Consultant
Medication Information Service
Torrance, California

Edward V. Platia, MD
Director, Cardiac Arrhythmia Center
Washington Hospital Center
Professor of Medicine
George Washington University School of Medicine

Michael T. Reed, PharmD
Associate Professor of Clinical Pharmacy
Arnold and Marie Schwartz College of Pharmacy and Health Sciences of Long Island University
Brooklyn, New York
The Mount Sinai Medical Center
New York, New York

J. James Rowsey, MD
Professor and Chairman
Department of Ophthalmology
University of South Florida
College of Medicine
Tampa, Florida

Frederick L. Ruben, MD
Infectious Disease Division
Montefiore University Hospital
University of Pittsburgh
Pittsburgh, Pennsylvania

Mary Beth Shirk, PharmD
Specialty Practice Pharmacist, Critical Care Medicine
Clinical Assistant Professor
The Ohio State University Medical Center
Columbus, Ohio

Burgunda V. Sweet, PharmD
Chief, Drug Information Services
The University of Michigan Hospitals
Ann Arbor, Michigan

Udho Thadani, MBBS, MD FRCP(C), FACC
Professor of Medicine
Vice Chief of Cardiology and Director of Clinical Research
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

Robert A. Wild, MD
Chief, Section of Research & Education in Women's Health
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

Thom J. Zimmerman, MD, PhD
Chairman of Department of Ophthalmology and Visual Sciences
Professor of Pharmacology & Toxicology
University of Louisville

Foreword

Facts and Comparisons® has served the drug information needs of pharmacists and other health care professionals since its inception in 1946 by providing timely, accurate, comprehensive, unbiased, comparative information on both prescription and nonprescription medications. *Drug Facts and Comparisons® (DFC),* our flagship product, is the primary source of drug information and the reference of choice for over 100,000 loyal subscribers because of its uncompromising editorial quality, reliability, and ease of use. *DFC* has remained unique among other drug information resources because of its organization by therapeutic use, providing single drug monographs with complete prescribing information as well as in-depth comparisons of closely related agents. Over the years, *DFC* has changed in size and scope, most recently in 2000 with the new format and monograph layout, but the concept has never changed. That is why health care professionals continue to look to Facts and Comparisons® to keep them abreast of important information in their practice.

In addition to the annual bound edition, *DFC* is also available as the popular monthly updated loose-leaf publication and as an annual pocket-size softbound abridged version. These versions allow customers to choose the format that is best suited to their practice site and workflow. Facts and Comparisons® is also devoting substantial resources to the new media that continue to revolutionize the information world. In addition to improving our print publications, we are committed to providing our drug information in any format that our customers prefer, utilizing the latest technologies.

In 1997, Facts and Comparisons® launched *CliniSphere®,* a CD-ROM containing a library of drug information products. The year 2000 brought many new advances to Facts and Comparisons®' product offerings, changing the way drug information can be accessed, including online versions of *Drug Facts and Comparisons®, Drug Interaction Facts™, The Review of Natural Products,* and *Med Facts™* (patient information handouts) as part of the *eFacts* family of online products. These new versions can be accessed via the Internet and can be adapted for use in company intranets and extranets as well. The *eFacts* online products, which will soon also include other publications, can be accessed through www.drugfacts.com, your drug information destination. Drugfacts.com offers credible, comprehensive, unbiased information from a variety of sources, including other Wolters Kluwer International Health & Science publishers and a host of other health care partners. The site also includes many interesting professional tools and services. Facts and Comparisons® also offers drug information for handheld personal data assistants, available for downloading at Drugfacts.com.

Facts and Comparisons® takes our mission of providing drug information to health care professionals very seriously, which is why we continue to invest in technology, improve our current publications, and stay in contact with our customers to make sure we maintain the high standards we set many years ago when Erwin Kastrup, RPh, first developed this concept. We have many people to thank for helping us achieve these goals, including our Editorial Advisory Panel, reviewers, contributors, and our excellent, dedicated employees, but more than anything we want to thank our loyal subscribers who have helped us develop and improve our drug information publications that are so widely used today.

We are dedicated to maintaining the traditions that are important to both Facts and Comparisons® and our customers, but we are also dedicated to evolving our products to meet the changing technologies and the changing needs of health care professionals. This can more easily be accomplished by comments and suggestions from our subscribers, which we encourage and appreciate. As always, let us know how we can better serve you and your drug information needs.

Steven K. Hebel, RPh
President and CEO

Preface

As the premier publisher of drug information, Facts and Comparisons® provides a broad range of print, electronic, and on-line resources to fulfill the day-to-day needs of practicing health care professionals. *Drug Facts and Comparisons® (DFC),* our flagship publication developed in 1945 by pharmacist Erwin K. Kastrup, was initially designed to provide objective information in a format that facilitated unbiased comparisons of drug products in a timely manner. After 55 years, the basic concepts remain the same. However, the content and presentation of material in *DFC* continues to evolve to reflect the changing needs of the health care environment.

Although the annual bound edition of *DFC* is one manner in which to access the primary source of drug information, we provide *DFC* in many formats to fit the specific needs of health care professionals. The original loose-leaf version is kept up to date through monthly print updates. An electronic version, also updated monthly, is available on CD-ROM as part of the *CliniSphere®* library of drug reference resources. The internet version of *DFC* became available in 2000 as part of *eFacts* and can be accessed via www.drugfacts.com, your drug information destination.

The new 56th edition of *DFC* incorporates 32 new drugs: Alemtuzumab (*Campath*), almotriptan malate (*Axert*), argatroban (*Acova*), arsenic trioxide (*Trisenox*), balsalazide disodium (*Colazal*), bimatoprost (*Lumigan*), bivalirudin (*Angiomax*), botulinum toxin type B (*Myobloc*), caspofungin acetate (*Cancidas*), cetrorelix acetate (*Cetrotide*), choriogonadotropin alfa (*Ovidrel*), crotalidae polyvalent immune fab (*CroFab*), esomeprazole magnesium (*Nexium*), fluticasone propionate/salmeterol (*Advair Diskus*), formoterol fumarate (*Foradil Aerolizer*), galantamine HBr (*Reminyl*), imatinib mesylate (*Gleevec*), insulin glargine (*Lantus*), iron sucrose (*Venofer*), levobetaxolol HCl (*Betaxon*), levofloxacin (*Quixin*), lopinavir/ritonavir (*Kaletra*), mifepristone (*Mifeprex*), nateglinide (*Starlix*), peginterferon alfa-2b (*PEG-Intron*), thyrotropin alfa (*Thyrogen*), tinzaparin sodium (*Innohep*), travoprost (*Travatan*), triptorelin pamoate (*Trelstar Depot*), unoprostone isopropyl (*Rescula*), valganciclovir (*Valcyte*), ziprasidone HCl (*Geodon*).

Significant new indications added include the following: Alendronate sodium for the prevention of osteoporosis in postmenopausal women and treatment of osteoporosis in men; amphotericin B for cryptococcal meningitis in HIV patients; anastrozole for first-line treatment of postmenopausal women with hormone-receptor positive or hormone-receptor unknown locally advanced or metastatic breast cancer; azelastine HCl for allergic conjunctivitis; enoxaparin sodium for the prevention of DVT in patients at risk for thromboembolic complications due to severely restricted mobility during acute illness; etanercept for the treatment of polyarticular-course juvenile rheumatoid arthritis; gabapentin for pediatric use; hydroxyurea for reducing the frequency of painful crises and reducing the need for blood transfusions in adults with sickle cell anemia with recurrent moderate to severe painful crises; infliximab for use in combination with methotrexate for reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis who have had inadequate response to methotrexate; mitoxantrone for use in multiple sclerosis; moxifloxacin HCl for uncomplicated skin and skin structure infections; mycophenolate mofetil for hepatic transplant; paroxetine HCl for generalized anxiety disorder; propofol for pediatric use; raloxifene for prevention and treatment of osteoporosis; ramipril for the reduction in risk of MI, stroke, and death from cardiovascular causes; risedronate sodium for the treatment and prevention of postmenopausal osteoporosis/glucocorticoid-induced osteoporosis; rosiglitazone maleate for combination use with a sulfonylurea; sulfasalazine for juvenile rheumatoid arthritis; and tamoxifen citrate for ductal carcinoma in situ.

Sections that have undergone major revisions include the following: Agents for Active Immunization, Androgens, Antituberculosis Agents, Antivenins, Beta-Adrenergic Blocking Agents, Fluoroquinolones, Immune Globulins, Insulins, Nicotine, and Toxoids.

As this edition goes to press, we continue to update our database daily for use in future editions and formats of *DFC*. We also continue to expand our extensive library of drug information resources to remain the full service drug information provider that our customers have come to expect. However, this can only be accomplished with feedback from the loyal health care professionals who use our information on a daily basis. Comments, criticisms and suggestions are always welcome and encouraged. Please call or visit us at www.drugfacts.com.

Kenneth H. Killion
Publisher

Introduction

Drug Facts and Comparisons® is a comprehensive drug information compendium. Organized by therapeutic drug class, the format is designed to provide a wide scope of drug information in a manner that facilitates evaluations and comparisons. A comprehensive index, a detailed table of contents for each chapter, and numerous cross references within monographs enable the reader to quickly locate needed information.

Editorial Policy

The principal editorial policy remains unchanged from the inception of *Drug Facts and Comparisons*® in 1945: Accurate, unbiased information; concise, standardized presentation; comparative, objective format; timely delivery. Review of FDA-approved product labeling, thousands of biomedical journal articles and textbooks, and policies and recommendations from many authoritative and official groups (eg, Centers for Disease Control; National Academy of Sciences; Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung and Blood Institute; American Thoracic Society; National Cancer Institute; FDA Office of Orphan Products Development; Food and Drug Administration) form the base of evaluation of information for *Drug Facts and Comparisons*®.

Editorial policy is guided by the distinguished Facts and Comparisons® Editorial Advisory Panel. This is an authoritative group of nationally and internationally recognized clinicians, scholars, scientists, physicians, pharmacists, and pharmacologists. Pages are reviewed by these eight panel members. In addition, many other prominent health care professionals serve on various expert panels and provide review in their specific areas of expertise for *Drug Facts and Comparisons*®. Indications and dosage recommendations are FDA-approved unless otherwise specified. Legitimate "unlabeled" uses and dosages are included when appropriate and given special emphasis. Input from an expert panel on drug interactions is also a feature.

This collection of wisdom and the world drug information literature is then molded and refined into the *Drug Facts and Comparisons*® database, monographs, and product listings. Many sources of drug information are constantly monitored so that *Drug Facts and Comparisons*® contains the most comprehensive, current drug information database available. There is not a more complete drug information compendium available presenting such clinical prescribing and drug product information.

Most of the products listed in *Drug Facts and Comparisons*® are protected by letters of patent, and their names are trademarked and registered by the firm whose name appears with the product. Identification of the product distributor is given in parentheses next to the brand name. The distributor may or may not be the actual manufacturer or fabricator of the final dosage form. When more than one company distributes a generic product, the generic product name is listed, followed by "Various, eg," in parentheses with a selected list of distributors. Listing of specific products is an indication only of market availability and is not an endorsement or recommendation. Most products listed have national or significant regional distribution.

Products that contain the same active ingredients are listed together for comparison and as an aid in product selection. However, drug product interchange is regulated by state laws; listing of products together does not imply that products are therapeutically equivalent or legally interchangeable. Caution is particularly advised when attempting to compare extended-release or delayed-release dosage forms.

How To Use *Drug Facts And Comparisons*®

Efficient use of *Drug Facts and Comparisons® (DFC)* requires an understanding of its organization and format.

Organization:

Information in *DFC* is organized by therapeutic use. Each of the 14 chapters is divided into groups and subgroups to facilitate comparisons of drugs and drug products with similar uses. The first page of each chapter provides a detailed outline, including page references of the information presented in that chapter.

Products most similar in content or use are listed together. This format of presenting the FACTS makes it easy to make COMPARISONS of identical, similar, or related products. Drugs with multiple uses may be listed in more than one section of the book.

Drug Monographs:

Prescribing information is presented in comprehensive drug monographs. General information on a group of closely related drugs (eg, ACE inhibitors) may be presented in a group monograph. Specific information relating to a particular drug is presented in an individual monograph under the generic name of the drug. All monographs are divided into sections identified with bold titles for ease in locating the desired information.

Indications: All indications or uses listed are FDA-approved unless specifically designated as "Unlabeled uses."

Administration and Dosage: Dosage ranges and methods of administration are presented.

Actions: This section gives a brief summary of the known pharmacologic and pharmacokinetic properties.

Contraindications: This section specifies those conditions in which the drug should NOT be used.

Warnings and Precautions: These sections list conditions in which use of the drug may be hazardous, precautions to observe, and parameters to monitor during therapy.

Drug Interactions: A brief summary of documented, clinically significant drug-drug, drug-lab test and drug-food interactions is provided.

Adverse Reactions: Reported adverse reactions are presented. Incidence data on adverse effects are included when available.

Overdosage: The clinical manifestations of toxicity and treatment of overdosage are given for most agents.

Patient Information: Essential information required by the patient for safe and effective self-administration of the medication is included.

Keeping Up:

The Keeping Up section enables the health care professional to stay up-to-date with the latest developments in drug therapy.

Orphan Drugs: Profiles the generic name and trade name of a drug, its sponsor, and the proposed use of an agent approved for marketing under the terms of the Orphan Drug Act.

Investigational Drugs: Provides brief reports on significant developments in drug therapy, including drugs currently under investigation.

Index:

The alphabetical index includes page references for all drugs by their generic name, brand name, synonyms, common abbreviations and therapeutic group names. Generic names are listed in bold type face for easy identification. A separate index of drug trade names unique to Canada is also a feature.

Product Listings:

Individual products are listed at the beginning of each monograph. The format and components of the product listings are discussed below and illustrated on the opposite page.

1. Products are grouped by dosage form or strength.
2. Identical brand name products are listed in alphabetical order.
3. The name of the distributor is given in parentheses next to the product name.
4. Products available by their generic name from multiple sources are indicated as available from (Various) distributors and in selected cases, examples of generic manufacturers are listed.
5. Package sizes are given for all dosage forms and strengths of each product.
6. Product identification imprint codes are listed in parentheses.
7. Cross references to the appropriate drug monograph(s) for complete prescribing information appear at the beginning of the monograph.
8. Controlled substances are designated by their schedule (*c-II, c-III, c-IV,* or *c-V*).
9. Distribution status of products is indicated as *Rx* or *otc.*
10. Sugar free liquid preparations are designated by *sf.*
11. Combination products are listed in tables to facilitate comparisons. Products most similar in formulation are listed next to each other.
12. Products with identical formulations are listed together.

Aminopenicillins

AMOXICILLIN

Rx	**Amoxil** (SK-Beecham)	**Tablets**: 500 mg (as trihydrate)	(Amoxil 500). Film-coated. Capsule shape. Pink. In 20s, 100s, 500s
		875 mg (as trihydrate)	(Amoxil 875). Film coated, scored. Capsule shape. Pink. In 20s, 100s, 500s.
Rx	**Amoxicillin** (Various, eg, Biocraft, Major, Rugby, Teva, URL)	**Capsules**: 250 mg (as trihydrate)	In 21s, 30s, 100s, 250s, 500s, 1000s and UD 45s and 100s.
Rx	**Amoxil** (SK-Beecham)		(Amoxil 250). Blue and pink. In 100s, 500s and UD 100s.
Rx	**Trimox** (Apothecon)		In 30s, 100s, 500s and UD 100s.
Rx	**Wymox** (Wyeth-Ayerst)		(Wyeth 559). Gray and green. In 100s and 500s.
Rx	**Amoxicillin** (Various, eg, Biocraft, Major, Rugby, Teva, URL)	**Capsules**: 500 mg (as trihydrate)	In 21s, 30s, 50s, 100s, 250s, 500s and UD 45s and 100s.
Rx	**Amoxil** (SK-Beecham)		(Amoxil 500). Blue and pink. In 100s, 500s and UD 100s.
Rx	**Trimox** (Apothecon)		In 30s, 100s, 500s and UD 100s.
Rx	**Wymox** (Wyeth-Ayerst)		(Wyeth 560). Gray and green. In 50s and 500s.
Rx	**Amoxil Pediatric Drops** (SK-Beecham)	**Powder for Oral Suspension**: 50 mg/ml (as trihydrate) when reconstituted	Sucrose. Bubble gum flavor. In 15 and 30 ml.
Rx	**Trimox Pediatric Drops** (Apothecon)		Sucrose. In 15 ml.
Rx	**Amoxicillin** (Various, eg, Biocraft, Major, Teva, URL)	**Powder for Oral Suspension**: 125 mg/5 ml (as trihydrate) when reconstituted	In 80, 100, 150 and 200 ml.
Rx	**Amoxil** (SK-Beecham)		Sucrose. Strawberry flavor. In 80, 100 and 150 ml and UD 5 ml.
Rx	**Trimox** (Apothecon)		Sucrose. In 80, 100 and 150 ml.
Rx	**Wymox** (Wyeth-Ayerst)		Sucrose. In 100 and 150 ml.
Rx	**Amoxicillin** (Various, eg, Biocraft, Major, Teva, URL)	**Powder for Oral Suspension**: 250 mg/5 ml (as trihydrate) when reconstituted	In 80, 100, 150 and 200 ml.
Rx	**Amoxil** (SK-Beecham)		Sucrose. Bubble gum flavor. In 80, 100 and 150 ml and UD 5 ml.
Rx	**Trimox** (Apothecon)		Sucrose. In 80, 100 and 150 ml.
Rx	**Wymox** (Wyeth-Ayerst)		Sucrose. In 100 and 150 ml.

For complete prescribing information, refer to the Penicillins group monograph.

Indications

Infections caused by susceptible strains of the following organisms: Gram-negative – *H. influenzae*, *E. coli*, *P. mirabilis* and *N. gonorrhoeae*. Gram-positive – Streptococci (including *S. faecalis*), *S. pneumoniae* and nonpenicillinase-producing staphylococci.

the advantage of more complete absorption than ampicillin, a 3-times a day regimen for most infections and less diarrhea than ampicillin.

Larger doses may be required for persistent or severe infections.

The children's dose is intended for individuals whose weight will not cause the calculated dosage to be greater than that recommended for adults; the children's dose should not exceed the maximum adult dose.

ANTITUSSIVE AND EXPECTORANT COMBINATIONS

	Product & Distributor	Decongestant	Antitussive	Antihistamine	Expectorant
c-v	**Robafen DAC Syrup** (Major)	30 mg pseudoephedrine HCl	10 mg codeine phosphate		100 mg guaifenesin
c-v sf	**Robitussin-DAC Syrup** (Robins)				
c-v sf	**Ryna-CX Liquid** (Wallace)				
c-v sf	**Tussar SF Syrup** (Rhone-Poulenc Rorer)				
c-v	**Tussar-2 Syrup** (Rhone-Poulenc Rorer)				
c-v sf	**Naldecon CX Adult Liquid** (Apothecon)	12.5 mg phenylpropanolamine HCl	10 mg codeine phosphate		200 mg guaifenesin
c-v sf	**Codegest Expectorant Liquid** (Great Southern)	12.5 mg phenylpropanolamine HCl	10 mg codeine phosphate		100 mg guaifenesin
c-v	**Conex w/Codeine Syrup** (Forest)				
c-v sf	**Endal Expectorant Syrup** (UAD)				
c-v	**Statuss Expectorant Liquid** (Huckaby)				
c-v	**Triaminic Expectorant w/Codeine Liquid** (Sandoz)				
otc	**Tussex Cough Syrup** (Various, eg, Barre-National, Moore, Rugby)	5 mg phenylephrine HCl	10 mg dextromethorphan HBr		100 mg guaifenesin
otc sf	**Dexafed Cough Syrup** (Mallard)				
Rx	**MED-Rx DM Tablets** (Iomed)	60 mg pseudoephedrine HCl			600 mg guaifenesin
			30 mg dextromethorphan HBr		
Rx	**Protuss DM Tablets** (Horizon)	60 mg pseudoephedrine HCl	30 mg dextromethorphan HBr		600 mg guaifenesin
otc	**Anatuss DM Tablets** (Mayrand)	60 mg pseudoephedrine HCl	20 mg dextromethorphan HBr		400 mg guaifenesin

Color Locator

The Color Locator is an aid in identifying tablets and capsules by their appearance. The products pictured include commonly used prescription drug products. Because of the similarity in size, shape, and color of products with significantly different ingredients, product identification should be confirmed by identifying imprints.

Organization

Products are arranged by doseform, color, size, and shape. Every effort has been made to accurately reproduce the color of each product. However, variations will occur and exact reproductions are sometimes impossible. See the Table of Contents below for doseform arrangement. The index begins on page CL-33.

Contents

Each product pictured is identified with the product trade name, strength, and manufacturer. For products with a product identification code imprint, the imprint is included following the manufacturer's name. Products are also indicated as prescription (℞) or controlled substance (C-II, C-III, C-IV, or C-V).

Slight variations of color and ID code may occur. Drug manufacturers are expanding the use of product imprints to identify products by name or ID code. During this transition, various lots of the same product may have differing imprints. The ID code following the manufacturer name may not appear on all products pictured.

Table of Contents

Light Gold to Yellow-Gold Tablets



Arava 20 mg
Aventis ZBO



Cardizem 120 mg
Aventis 120



Thioguanine 40 mg
GlaxoWellcome U3B



Lamictal 150 mg
GlaxoWellcome 150



Cardizem 60 mg
Aventis Marion 1772



Zaroxolyn 10 mg
Medeva 10



Dilantin Infatab 50 mg
Parke-Davis P-D 007



Aldactone 25 mg
Pharmacia Searle 1001 25



Requip 0.5 mg
SmithKline Beecham SB 4891



Prinivil 10 mg
Merck MSD 106



Vasotec 2.5 mg
Merck MSD 14

Ritalin 20 mg
Novartis Ciba 34

Requip 1 mg
SmithKline Beecham SB 4892



Serzone 200 mg
B-M Squibb BMS 200 33



Floxin 200 mg
Ortho-McNeil 200



Naprosyn 500 mg
Roche 500



Zomig 2.5 mg
AstraZeneca Zomig 2.5

Zocor 5 mg
Merck MSD 726



Zestril 40 mg
AstraZeneca 40 134



Aricept 10 mg
Pfizer Aricept 10



NegGram 250 mg
Sanofi-Synthelabo W N 21



NegGram 500 mg
Sanofi-Synthelabo W N 22



NegGram 1 g
Sanofi-Synthelabo W N 23



Nor-QD
Pharmacia Watson 235



Floxin 400 mg
Ortho-McNeil 400



Seroquel 100 mg
AstraZeneca 100



Luvox 50 mg
Solvay 4205



OxyContin 40 mg
Purdue Pharma OC 40



Mevacor 10 mg
Merck MSD 730



Sular 10 mg
AstraZeneca 10 891

Zoloft 100 mg
Roerig 100



Actonel 5 mg
Procter & Gamble RSN 5 mg



Glucovance 1.25 mg/250 mg
B-M Squibb BMS 6072



Lescol XL 80 mg
Novartis LESCOL XL 80



Topamax 100 mg
Ortho-McNeil 100



Aciphex 20 mg
Janssen E 243

CL-4 Yellow-Gold to Yellow Tablets



Trileptal 150 mg
Novartis CG CG TD TD



Etodolac 400 mg
Watson 667 400



Baycol 0.4 mg
Bayer 285 400 MCG



Clinoril 150 mg
Merck MSD 941



Trileptal 300 mg
Novartis CG CG TE TE



Tonocard 600 mg
AstraZeneca 709



Voltaren 25 mg
Novartis 25



Clinoril 200 mg
Merck MSD 942



Trileptal 600 mg
Novartis CG CG TF TF



Sular 20 mg
AstraZeneca 20 892



Atarax 50 mg
Roerig 50



Paxil 10 mg
SmithKline Beecham 10



Ziagen 300 mg
GlaxoWellcome GX 623

Cardura 2 mg
Roerig 2



Prolixin 2.5 mg
Apothecon PPP 864



Mellaril 150 mg
Novartis 150



Glucovance 5 mg/500 mg
B-M Squibb BMS 6074



Risperdal 0.25 mg
Janssen Ris 0.25



Desipramine HCl 25 mg
Watson 808



Zantac 300 mg
GlaxoWellcome 300



Starlix 120 mg
Novartis STARLIX 120



Wellbutrin 75 mg
GlaxoWellcome 75

Berocca Plus
Roche



Vivactil 10 mg
Merck MSD 47



Felbatol 400 mg
Wallace 04 30



Norpramin 25 mg
Aventis 25



Femara 2.5 mg
Novartis CG FV



K-Tab 10 mEq
Abbott



Felbatol 600 mg
Wallace 04 31



Naturetin 10 mg
Apothecon 10 PPP 618

Menest 0.3 mg
King Pharmaceuticals M72



Proloprim 200 mg
Monarch 200



Tonocard 400 mg
AstraZeneca 707



Voltaren 50 mg
Novartis 50

Klor-Con 10 10 mEq
Upsher-Smith 10

Coumadin 7.5 mg
DuPont Coumadin 7 1/2

Yellow to Light Green Tablets

℞



Renese 2 mg
Pfizer 376

℞

Zofran 8 mg
GlaxoWellcome 8

C-IV

Clonazepam 0.5 mg
Watson 746

C-IV

Talwin NX
Sanofi-Synthlabo W T51

℞

Thioridazine HCl 10 mg
Mutual MP 12

℞

Sinemet-25/100
DuPont 650

℞

Levothroid 100 mcg
Forest Pharm 100

C-II

Oxycodone/Aspirin 4.5/0.38/325 mg
Watson 820

℞

Thioridazine HCl 25 mg
Mutual MP 14

℞

Perphenazine/Amitriptyline HCl 4/25 mg
Watson 709 4-25

℞

Decadron 0.5 mg
Merck MSD 41

C-II

Ritalin 5 mg
Novartis Ciba 7

℞



Thioridazine HCl 50 mg
Mutual MP 17

℞

Cantil 25 mg
Aventis Merrell 37

℞

Clozaril 100 mg
Novartis 100

℞

Glyburide 6 mg
Watson M07 6.0

℞

Thioridazine HCl 100 mg
Mutual MP 160

℞

Propranolol 80 mg
Sidmak SL 471

℞

Synthroid 0.1 mg
Knoll Flint 100

℞

Calan SR 240 mg
Pharmacia SR 240

℞

Levatol 20 mg
Schwarz Pharma SP22

℞

Dymelor 500 mg
Lilly U07

℞

Bumex 1 mg
Roche 1

℞

Isordil Tembids 40 mg
Wyeth-Ayerst 4125

℞

Elavil 25 mg
AstraZeneca 45

℞



Urecholine 25 mg
Merck MSD 457

℞

Sorbitrate 10 mg
AstraZeneca S 780

℞

Esidrix 50 mg
Novartis Ciba 46

℞

Hiprex 1 g
Aventis Merrell 277

℞

Urecholine 50 mg
Merck MSD 460

℞

Risperdal 3 mg
Janssen R 3

℞

Lanoxin 0.125 mg
GlaxoWellcome Y3B

℞

Flexeril 10 mg
Merck MSD 931

C-IV

Valium 5 mg
Roche 5

C-II

Dilaudid 4 mg
Knoll K 4

℞

Clozaril 25 mg
Novartis 25